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Hepatoactive substances eliminated by continuous venovenous spite modern critical care medicine. On the one hand, this
hemofiltration in acute renal failure patients. fact could be explained by the rising number of patients
Background. Acute renal failure (ARF) in critically ill pa- with multiple organ failure (MOF). On the other hand,tients is mostly part of a multi-organ failure. Therefore, the
ARF in the critical care setting is rarely a single organeffects of renal replacement therapy on the liver are clinically
important. We investigated the effects of ultrafiltrates of pa- failure, but mostly occurs as part of a MOF [1]. In patients
tients treated with continuous venovenous hemofiltration with MOF, mortality directly correlates with the number
(CVVH) on liver cells in vitro. of failing organ systems [1]. An additional hepatic failureMethods. Patients with ARF were consecutively treated
was found to be especially and significantly related towith CVVH using Multiflow60 (group I) or FH66 filters (group
II). They were comparable with respect to diagnosis, age, sex, mortality [2]. Continuous forms of renal replacement
laboratory parameters, and renal replacement treatment, but therapies (CRRTs) with a polyacrylonitrile membrane
were different in daily diuresis, serum levels, and blood flow. were shown to improve the clinical course and to increaseUltrafiltrates were collected within the first 10 minutes after
the survival of patients with hepatic failure and ARF [3].change of hemofilter. Proliferation (bromodeoxyuridine), vital-
Hemofiltration (HF) using polyacrylonitrile membraneity (lactate dehydrogenase), and acute-phase protein secretion
of HepG2 cells were measured. resulted in smaller adverse changes in intracranial pres-
Results. Ultrafiltrates changed liver cell function signifi- sure, mean arterial blood pressure, cerebral perfusion
cantly compared with medium control. Proliferation (group I
pressure, and tissue oxygen delivery [4]. The increase in29.8 6 5.2% vs. group II 48.4 6 6.6%, P , 0.05) and vitality
survival could be due to the removal of middle molecular(group I 78.7 6 2.0% vs. group II 87.6 6 1.7%, P , 0.01) of
HepG2 cells were significantly different. On the one hand, the weight compounds, which have been thought to be impor-
secretion of the negative acute-phase protein transferrin [group tant in the pathogenesis of hepatic coma.
I 3.1 6 0.2 (ng/mg protein) vs. group II 5.1 6 0.5 (ng/mg protein),
Correspondingly, toxic mediators (cytokines, cyclicP , 0.01] was significantly reduced by Multiflow60 ultrafiltrates.
endoperoxides, and so forth) have been identified inOn the other hand, positive acute-phase protein a1-acid glyco-
protein was significantly stimulated by Multiflow60 ultrafiltrates ultrafiltrates taken during continuous venovenous HF
[group I 2.6 6 0.1 (ng/mg protein) vs. group II 1.7 6 0.1 (ng/mg (CVVH) with polyamide from septic patients [5]. How-
protein), P , 0.001].
ever, the possibility that HF also improves specific organConclusion. This study demonstrates hepatoactive media-
failure in MOF is a point of controversy.tors in the ultrafiltrates. They are hepatotoxic and influence
acute-phase protein metabolism. Further studies have to eluci- The aim of this study was to examine hepatoactive medi-
date the different effects in both groups and the analysis of the ators in the ultrafiltrate of critically ill patients with ARF.
putative mediator(s). It remains a challenging task to consider Therefore, we investigated the effects of ultrafiltratestherapeutic measures to optimize renal replacement therapy
of patients treated either with Multiflow60 or FH66 onin critically ill patients.
liver cells in vitro (HepG2). Several parameters of cell
function [proliferation, lactate dehydrogenase (LDH)-
release, acute-phase protein secretion] were measured.Acute renal failure (ARF) in the intensive care unit
(ICU) is a multifactorial clinical syndrome that is charac-
terized by an abrupt but potentially reversible reduction
METHODSin excretory renal function. The prognosis of patients
Patientswith ARF has not improved during the past decades de-
Thirty-one patients with ARF at the ICU of the Uni-
versity Hospital of Saarland were studied. ARF was con-Key words: multiple organ failure, critical care, ultrafiltrates, hepato-
toxins, continuous venovenous hemofiltration. sidered when urine output was ,200 ml/12 hr, despite
maximal conventional therapy, and at least one addi- 1999 by the International Society of Nephrology
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Table 1. Patient characterization 1640, Biochrom F1215) containing 10% fetal calf serum,
1% glutamine, and 1% streptomycin/penicillin. Cells wereGroup I Group II
(N 5 16) (N 5 15) P value weekly subcultured and seeded in 96- or 24-well plates
Gender female/male 7/9 7/8 (No. 655180; Greiner Labortechnik, Solingen, Germany)
Age years 60.364.6 56.164.9 NS in a density of 100,000 cells per well or 500,000 cells per
Serum creatinine mg/dl 3.060.3 3.2 6 0.3 NS
well. After 24 hours, growth medium was removed, andUrea mg/dl 117.8613.7 163.6617.0 ,0.05
Uric acid mg/dl 13.167.9 7.261.5 NS cells were incubated for 24 to 48 hours with ultrafiltrates
Residual rest function of the two different hemofilters. All media had a lowml/24 hr 1085.36313.7 341.06147.4 ,0.05
endotoxin level (#0.2 EU/ml). The vitality of cells, asGOT U/liter 181.8681.2 52.9618.9 NS
GPT U/liter 79.2643.6 53.7626.8 NS assessed by trypan blue exclusion test, was always greater
CHE U/liter 2.460.1 2.160.18 NS than 95%.Mortality N 5 9 N 5 7 NS
Patients were treated with different hemofilters: Group I, Multiflow60; Group AssaysII, FH66. Data are presented as mean 6 sem. Statistics were performed by the
Student’s t-test. Abbreviations are: GOT, glutamic-oxaloacetic transaminase; LDH assay. Cytotoxicity of ultrafiltrates was assessed
GPT, glutamic-pyruvic transaminase; CHE, cholinesterase.
by the release of LDH into the medium. Measurements
were performed using a commercially available assay
(Roche Diagnostics GmbH., Mannheim, Germany) ac-
tional organ failure occurred. The cause of ARF was cording to the instructions of the manufacturer.
cardiac shock, sepsis, or trauma. Proliferation assay. Cellular proliferation was deter-
Patients were treated consecutively with CVVH using mined by bromodeoxyuridine (BrdU) incorporation us-
either (group I) hollow fiber polyacrylonitrile hemofilter ing a commercially available assay (Roche Diagnostics
(Multiflow60; Hospal, Nu¨rnberg, Germany) or (group GmbH., Mannheim, Germany). Following labeling with
II) polyamide hollow fiber hemofilter (FH66; Gambro BrdU, incorporated BrdU was detected using a peroxi-
Co., Hechingen, Germany). In total, 16 patients were dase conjugated anti-BrdU antibody. The substrate reac-
treated with Multiflow60 hemofilters, and 15 patients tion was terminated by 1 m sulfuric acid, and absorbences
were treated with the FH66 hemofilter. were read at 450 nm. Medium controls were arbitrarily
The mean age and liver specific parameters [glutamic- set at 100%.
oxaloacetic transaminase (GOT), glutamic-pyruvic trans- Enzyme-linked immunosorbent assay (ELISA) of acute-
aminase (GPT), and cholinesterase (CHE)] of patients in
phase proteins (transferrin, a1-acid glycoprotein). Acute-
both groups did not differ (Table 1). The urea concentra-
phase proteins were measured in cell-conditioned media
tion and residual renal function measured by the amount
after 48 hours of incubation with different ultrafiltrates.of daily urine production were significantly lower in
Immunoplates (NUNC, Wiesbaden, Germany) weregroup II (Table 1).
coated with first antibody (mouse anti-human transferrin
or a1-acid glycoprotein, Biogenesis, Berlin, Germany)Ultrafiltrate collection and treatment protocol
overnight at 48C, blocked with 100 ml of phosphate buf-Vascular access was provided by double-lumen dial-
fered saline (PBS)/0.05% Tween 20/0.25% bovine serumysis catheter of the jugular or femoral vein. Each hemo-
albumin (BSA), and incubated with 100 ml of antigenfilter and blood lines were initially rinsed with 2 liters
(standard of transferrin or a1-acid glycoprotein, Biogene-of normal saline solution, including IE heparin. Patients
sis, Berlin, Germany) or cell supernatant for one hour atwere connected directly to the extracorporal circuit.
room temperature. PBS/Tween-buffer was used for wash-Blood flow was 60 to 80 ml/min for group I (machine
ing between each step. The ELISA sandwich was com-type: BSM21; Hospal) and 100 to 120 ml/min for group
peted by horseradish peroxidase-conjugated antibodyII (machine type: ADM08; Fresenius Medical Care, Bad
(transferrin or a1-acid glycoprotein, Biogenesis, Berlin,Homburg, Germany). Heparin is given by 500–1000 IE/hr.
Germany). O-phenylendiamine dihydrochloride (OPD;The first 50 ml of ultrafiltrate were removed in order to
Sigma-Aldrich Co., Deisenhofen, Germany) was used asavoid contamination with rinsing solution. Thereafter,
substrate solution. The reaction was terminated with 4 m100 ml of pure ultrafiltrate (without rinsing solution,
sulfuric acid, and the absorbences were measured in awithout dialysate) were collected for analysis. Samples
Dynatech microplate reader at dual wavelength (490 andwere cooled on ice, sterile filtered (0.2 mm), aliquoted
630 nm). The results were calculated by nonlinear regres-under a laminar flow hood, and stored at 2208C until
sion analysis.further use.
Protein detection in cell culture assay. Cells were lyzed in
Culture techniques 0.1 m NaOH by overnight incubation at room temperature.
Protein content was measured with a slightly modified Brad-Hepatoma-derived cell line HepG2 (ATCC: HB-8065)
were routinely cultured in RPMI-growth medium (RPMI ford-Assay using bovine serum albumin for calibration.
Riegel et al: Elimination of hepatoactive substances by CVVH S-69
Fig. 1. Effects of ultrafiltrates on HepG2 cells. HepG2 cells were incu-
Fig. 2. Effect of ultrafiltrates on transferrin secretion by HepG2 cells.bated with different ultrafiltrates for 24 hours [( ), group I, Multiflow60
Cells were incubated with different ultrafiltrates for 48 hours [group I,(N 5 16), or (h) group II: FH66 (N 5 15)]. LDH release (vitality) and
Multiflow60 (N 5 16), or group II, FH66 (N 5 15)]. Secreted transferrinproliferation (BrdU incorporation) were determined as described in the
was measured by ELISA. Data (ng/mg total protein) are presented asexperimental procedures. Data are presented as mean 6 sem. Statistical
box-plot diagrams, with the box encompassing the range of values fromdifferences are analyzed by one-way analysis of variance. Vitality:
the 25% percentile (lower bar) to the 75% percentile (upper bar). The**group I vs. group II, P , 0.01. Proliferation: *group I vs. group II,
horizontal line within the box represents the median, and the linesP , 0.05.
above and below the box signify the maximum and minimum values.
Statistical differences were analyzed by one-way analysis of variance.
**Group I vs. group II: P , 0.01; *Group I vs. medium control: P , 0.05.
Statistics
All data were expressed as mean 6 sem. Statistical
differences were tested by Student’s t-test or by one-way
analysis of variance.
RESULTS
Effects of ultrafiltrates on bromodeoxyuridine
incorporation and lactate dehydrogenase release
Incubation of liver cells with ultrafiltrates significantly
influenced their integrity and functionality compared
with cells incubated with culture medium (Figs. 1–3).
Proliferation (group I 29.8 6 5.2% vs. group II 48.4 6
Fig. 3. Effect of ultrafiltrates on a1-acid glycoprotein (AGP) secretion6.6%, P , 0.05; Fig. 1) and vitality (group I 78.7 6 2.0%
by HepG2 cells. Cells were incubated with different ultrafiltrates forvs. group II 87.6 6 1.7%, P , 0.01; Fig. 1) of HepG2 48 hours [group I: Multiflow60 (N 5 16) or group II: FH66 (N 5 15)].
cells were significantly stronger inhibited by Multiflow60 Secreted AGP was measured by ELISA. Data (ng/mg total protein)
of three different incubation experiments are presented as box-plotultrafiltrates (group I).
diagrams, with the box encompassing the range of values from the 25th
percentile (lower bar) to the 75th percentile (upper bar). The horizontalEffects of ultrafiltrates on acute-phase
line within the box represents the median, and the lines above and
protein secretion below the box signify the maximum and minimum values. Statistical
differences were analyzed by one-way analysis of variance. ***GroupSecretion of the negative acute-phase protein trans-
I vs. group II: P , 0.001; ***Group I vs. medium control: P , 0.001.
ferrin in the supernatants of HepG2 cells was signifi-
cantly reduced by Multiflow60 ultrafiltrates (group I)
compared with medium control (group I: 3.1 6 0.2 ng/mg
protein vs. group II 5.1 6 0.5 ng/mg protein, P , 0.01; failure [6]. The major advantages of CRRT compared
group I vs. medium control 4.8 6 0.5 ng/mg protein, P , with intermittent hemodialysis are improved cardiovas-
0.05; Fig. 2). cular stability, maintenance of cerebral perfusion, ade-
On the other hand, secretion of the positive acute-phase quate metabolic control, and effective control of fluid
protein AGP (a1-acid glycoprotein) was significantly stim- balance, allowing adequate nutritional intake.
ulated by Multiflow60 ultrafiltrates compared with me- With respect to liver failure, literature is scarce. How-
dium control (group I 2.6 6 0.1 ng/mg protein vs. group ever, during bridging of acute liver failure patients to
II 1.7 6 0.1 ng/mg protein, P , 0.001; group I vs. medium
liver transplantation, the use of CRRT is recommendedcontrol 1.7 6 0.1 ng/mg protein, P , 0.001; Fig. 3).
in the initial stage of kidney failure [7].
Studies demonstrating the effects of replacement ther-
DISCUSSION apies in a prospective randomized fashion were not avail-
able until now.Continuous renal replacement therapies are known
to have benefits in patients suffering from multi-organ Our data demonstrate that ultrafiltrates eliminated
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from patients with multiorgan failure activate hepatic that should be investigated in detail in the future. Differ-
ences between the ultrafiltrates of the two membranesacute-phase response and impair liver cell function.
Currently, we cannot describe the exact nature of all (Multiflow60 vs. FH66) have to be elucidated. Detailed
biochemical analyses of the putative mediators must bemediators removed by HF and the individual biological
significance of their removal. A key finding from the done to identify their natures. Clinical randomized stud-
ies should try to clarify the effects of CRRT on liverincubation experiments was that ultrafiltrates signifi-
function.cantly inhibited proliferation and vitality of HepG2 cells.
Besides their suppressing qualities, CVVH ultrafil-
Reprint requests to Dr. Werner Riegel, Innere Medizin IV Medizin-trates also demonstrated a stimulating effect on acute-
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phase protein secretion. The exact mechanism of ultra- E-mail: inwrie@med-rz.uni-sb.de
filtrate-stimulated acute-phase protein response cannot
be determined by our experiments. Involvement of cyto-
REFERENCESkines seem to be unlikely, especially because Multiflow60
1. Druml W: Prognosis of acute renal failure 1975–1995. (editorial)membrane in contrast to FH66 membrane is known to
Nephron 73:8–15, 1996adsorb great amounts of cytokines during the first 15 to
2. Yuasa S, Takahashi N, Shoji T, Uchida K, Kiyomoto H, Hashi-
30 minutes of HF [8–10]. Besides this, their filtration moto M, Fujioka H, Fujita Y, Hitomi H, Matsuo H: A simple
and early prognostic index for acute renal failure patients requiringthrough membranes is limited by their molecular size,
renal replacement therapy. Artif Organs 22:273–278, 1998plasma protein binding, and receptor bindings [10]. How- 3. Davenport A, Will EJ, Davison AM: Effect of renal replacement
ever, C5a and possibly hepatocyte growth factor (HGF; therapy on patients with combined acute renal and fulminant he-
patic failure. Kidney Int 41(Suppl):S245–S251, 199335 to 70 kDa), which has an additional antiproliferative
4. Davenport A, Davison AM, Will EJ: Membrane biocompatibil-effect on HepG2 cells, could be potential mediators of ity: Effects on cardiovascular stability in patients on hemofiltration.
the acute-phase protein synthesis of HepG2 cells [11, 12]. Kidney Int 41(Suppl):S230–S234, 1993
5. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, In-Nevertheless, Multiflow60 membranes were found to ad-
thorn D: Hemofiltration in human sepsis: Evidence for eliminationsorb large amounts of complement components, and the of immunomodulatory substances. Kidney Int 48:1563–1570, 1995
6. Bellomo R, Mehta R: Acute renal replacement in the intensivemolecular weight of HGF is above the cut-off point of
care unit: Now and tomorrow. New Horiz 3:760–767, 1995the synthetic membranes.
7. Schetz MR: Classical and alternative indications for continuous
Our data also demonstrate different effects of ultrafil- renal replacement therapy. Kidney Int 66(Suppl):S129–S132, 1998
8. Barrera P, Janssen EM, Demacker PN, Wetzels JF, van Dertrates on liver cells with regard to both treatment groups.
MJ: Removal of interleukin-1 beta and tumor necrosis factor fromOne reason for this could be due to the different elimina-
human plasma by in vitro dialysis with polyacrylonitrile mem-
tion behavior of the two membranes used. Some other branes. Lymphokine Cytokine Res 11:99–104, 1992
9. Lonnemann G, Koch KM, Shaldon S, Dinarello CA: Studiesreasons for the measured in vitro effects might be the
on the ability of hemodialysis membranes to induce, bind, anddifferences in patients and treatment protocol. Diuresis clear human interleukin-1. J Lab Clin Med 112:76–86, 1988
and urea serum levels of patients differed in both treat- 10. van Bommel EFH, Hesse CJ, Jutte NH, Zietse R, Bruining HA,
Weimar W: Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) duringment groups (Table 1). Furthermore, different types of
continuous hemofiltration: A laboratory and clinical study. Contribmachines had to be used for treatment (BSM21 vs. Nephrol 116:62–75, 1995
ADM08) requiring different blood flow through dialyz- 11. Koj A, Korzus E, Baumann H, Nakamura T, Travis J: Regulation
of synthesis of some proteinase inhibitors in human hepatoma cellsers in both groups. Moreover, ultrafiltrates were col-
HepG2 by cytokines, hepatocyte growth factor and retinoic acid.
lected only at one time point (that is, filter change of Biol Chem Hoppe Seyler 374:193–201, 1993
12. Buchner RR, Hugli TE, Ember JA, Morgan EL: Expression ofthe 24-hr treatment period). Thus, the data do not reflect
functional receptors for human C5a anaphylatoxin (CD88) on theall the effects of ultrafiltrate over 24 hours.
human hepatocellular carcinoma cell line HepG2: Stimulation of
In conclusion, hepatoactive mediators can be ultrafil- acute-phase protein-specific mRNA and protein synthesis by hu-
man C5a anaphylatoxin. J Immunol 155:308–315, 1995trated by highly biocompatible synthetic membranes in
13. Grootendorst AF, Van BE, Van-Der HB, Van LL, Van OA:critically ill patients with ARF. They are hepatotoxic
High-volume hemofiltration improves right ventricular function in
and can stimulate the acute-phase response. Therefore, endotoxin-induced shock in the pig. Intensive Care Med 18:235–240,
1992CRRT might be of potential benefit in order to prevent
14. Stein B, Pfenninger E, Grunert A, Schmitz JE, Hudde M: Influ-hepatic failure. This view is supported by recent investi- ence of continuous haemofiltration on haemodynamics and central
gations in which isovolemic HF improved specific organ blood, in experimental endotoxic shock. Intensive Care Med
16:494–499, 1990failure in septic animals [13–15] and by positive clinical
15. Stein B, Pfenninger E, Grunert A, Deller A: Influence of con-results in critically ill ARF patients with fulminant he- tinuous hemofiltration on hemodynamics and pulmonary function
patic failure [3]. However, there are some primary topics in porcine endotoxic shock. Contrib Nephrol 93:105–109, 1991
